Sarepta Therapeutics Gains FDA Approval for Elevidys Study
The U.S. Food and Drug Administration (FDA) has given the green light to Sarepta Therapeutics Inc. (NASDAQ: SRPT) to commence dosing in Cohort 8 as part of its ENDEAVOR study.
Objectives of Cohort 8
The main goal of Cohort 8 is to assess the ability of an enhanced immunosuppression regimen to assist individuals with Duchenne muscular dystrophy (DMD) who are non-ambulant in receiving Elevidys (delandistrogene moxeparvovec-rokl).
Understanding Acute Liver Injury Risks
Key data from this cohort will reveal whether giving sirolimus before and after the Elevidys infusion can lower the risks associated with acute liver injury (ALI). Sirolimus serves as an immunosuppressant aimed at preventing adverse reactions during the therapy.
Sarepta's Commitment to Safety
This year's reports have highlighted three fatalities linked to acute liver failure in individuals treated with either Elevidys or an experimental gene therapy similar to the AAVrh74 technology. Notably, one incident occurred during a clinical trial targeting limb girdle muscular dystrophy.
Study Details and Enrollment
A total of approximately 25 participants will be enrolled in this study across the U.S. These individuals are unable to walk, and the immunosuppression plan will consist of 14 days of sirolimus treatment around the time of Elevidys administration, followed by an additional 12 weeks post-treatment.
Endpoints and Effectiveness
Primary objectives include monitoring the rate of ALI and measuring Elevidys-induced dystrophin expression at the 12-week mark. This will help gauge the treatment's effectiveness in DMD patients.
Elevidys: A Unique Gene Therapy
Elevidys holds the distinction of being the only FDA-approved gene therapy specifically targeting Duchenne muscular dystrophy, highlighting Sarepta's innovative approach in the field of genetic treatments. The ENDEAVOR study, known by the identifier SRP-9001-103, is a pivotal open-label Phase 1b assessment aimed to track the expression and overall safety of Elevidys across various cohorts of boys diagnosed with DMD.
Progress Across Multiple Cohorts
The ongoing study has successfully enrolled around 55 participants so far, incorporating individuals from different age groups, including younger ambulatory boys aged 2-7, older moving boys, as well as non-ambulatory patients.
Measuring Treatment Outcomes
The primary endpoint of the ENDEAVOR study is to analyze changes from baseline in the levels of Elevidys micro-dystrophin protein, as gauged through western blotting techniques after 12 weeks of treatment. Additionally, secondary measures involve examining alterations from baseline in micro-dystrophin expression evaluated by the percentage of dystrophin-positive muscle fibers in the same duration.
Recent Developments in Clinical Trials
On a related note, Sarepta has recently announced milestones in the Phase 1/2 clinical study for SRP-1003 (previously named ARO-DM1), a promising treatment aimed at addressing type 1 myotonic dystrophy. The initial two cohorts (1.5 mg/kg and 3 mg/kg) have been wrapped up, and enrollment for the third cohort (4.5 mg/kg) is currently in progression.
Collaboration with Arrowhead Pharmaceuticals
A significant milestone recognized in this process activated a $200 million financial trigger for Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), reinforcing the collaborative effort between both companies in advancing innovative treatments.
Stock Update and Market Reaction
As per recent market performance, Sarepta Therapeutics saw its stock price appreciate by 1.90%, reaching $19.27 around the time of the announcement, indicating positive investor sentiment towards the company’s ongoing research and future potential.
Frequently Asked Questions
What is the main objective of Cohort 8 in the study?
The main goal is to evaluate whether an enhanced immunosuppression regimen can reduce acute liver injury risk during Elevidys treatment for Duchenne muscular dystrophy patients.
How many participants will be enrolled in the study?
Approximately 25 participants, who are non-ambulant, will be enrolled in Cohort 8 of the study.
What specific treatments are included in the immunosuppression regimen?
The regimen includes 14 days of peri-infusion dosing with sirolimus prior to the Elevidys administration, followed by continued treatment for 12 weeks.
What are the primary endpoints being measured in this study?
The study aims to monitor the incidence of acute liver injury and the level of Elevidys-dystrophin expression at 12 weeks post-treatment.
Which companies are collaborating on related therapies?
Sarepta is collaborating with Arrowhead Pharmaceuticals, which is involved in the development and research of several related therapies.
